Delivery Order SPE2DB20D2104-SPE2DB21FT56R
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,493.27 firm-fixed-price delivery order is for the supply of LINZESS 290 MCG CAPSULE UU 30S, a pharmaceutical product. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which serves as a primary vehicle...
- This federal contract award, valued at $1,528.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for LINZESS 290 MCG CAPSULE UU 30S, a pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies...
- This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, was made by the Defense Logistics Agency (DLA) for the delivery of LINZESS 145 MCG capsules. The $11,706.10 firm fixed price delivery order contract has a completion date of June 10, 2024. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,854.76 firm fixed-price delivery order is for the supply of LINZESS 145 MCG capsules. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,451.78 fixed-price delivery order is for the supply of LINZESS 290 MCG capsules to support military healthcare programs. The contract has an ultimate completion date of March 8, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,810.50 firm fixed-price delivery order (SPE2DB22D2005|SPE2DB24FJJE9) is for the supply of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as the...
- This federal contract award, valued at $7,287.43, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, a Delivery Order under the DLA's Indefinite Delivery Contract (IDC) valued at $999,999,999, covers the supply of Linzess 290 MCG Capsules to support military healthcare programs. The contract has an ultimate completion date of October 30, 2024 and is a Firm Fixed Price arrangement....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of LINZESS 290 MCG capsules. The $1,415.00 firm fixed price delivery order has an ultimate completion date of October 10, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award, valued at $4,803.82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under an Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to...
- This federal contract award, issued by the Defense Logistics Agency (DLA), is a delivery order valued at $7,982.53 for the pharmaceutical product LINZESS 290 MCG CAPSULE UU 30S. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB21FT56RDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,554.06 delivery order contract is for the supply of Linzess 290 MCG capsules. The award is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions globally. The contract does not have a set-aside designation, indicating it was awarded through full and open competition. AmerisourceBergen's parent company is Cencora, Inc., which also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 8/5/21 |